Initially, gene therapy was viewed as an approach for treating hereditary diseases, but its potential role in the treatment of acquired diseases such as cancer is now widely recognized. The understanding of the molecular mechanisms involved in cancer and the development of nucleic acid delivery systems are two concepts that have led to this development. Systemic gene delivery systems are needed for therapeutic application to cells inaccessible by percutaneous injection and for multi-located tumor sites, i.e. metastases. Non-viral vectors based on the use of cationic lipids or polymers appear to have promising potential, given the problems of safety encountered with viral vectors. Using these non-viral vectors, the current challenge is to obtain a similarly effective transfection to viral ones. Based on the advantages and disadvantages of existing vectors and on the hurdles encountered with these carriers, the aim of this review is to describe the "perfect vector" for systemic gene therapy against cancer.
Systemic gene delivery systems are needed for therapeutic application to organs that are inaccessible by percutaneous injection. Currently, the main objective is the development of a stable and non-toxic vector that can encapsulate and deliver foreign genetic material to target cells. To this end, DNA, complexed with cationic lipids i.e DOTAP/DOPE, was encapsulated into lipid nanocapsules (LNCs) leading to the formation of stable nanocarriers (DNA LNCs) with a size inferior to 130nm. Amphiphilic and flexible poly (ethylene glycol) (PEG) polymer coatings [PEG lipid derivative (DSPE-mPEG 2000 ) orF108 poloxamer] at different concentrations were selected to make DNA LNCs stealthy. Some of these coated lipid nanocapsules were able to inhibit complement activation and were not phagocytised in vitro by macrophagic THP-1 cells whereas uncoated DNA LNCs accumulated in the vacuolar compartment of THP-1 cells. These results correlated with a significant increase of in vivo circulation time in mice especially for DSPE-mPEG 2000 10mM and an early half-life time (t 1/2 of distribution) 5-fold greater than for non-coated DNA LNCs (7.1h vs 1.4h). Finally, a tumor accumulation assessed by in vivo fluorescence imaging system was evidenced for these coated LNCs as a passive targeting without causing any hepatic damage. Furthermore, when injected intravenously, colloidal carriers are rapidly cleared by the mononuclear phagocyte system (MPS) mainly represented by Kupffer cells in the liver and spleen macrophages. The recognition of the carriers by macrophages usually occurs through specific recognition by cellular receptors specific for plasma proteins that have been adsorbed at the vector surface. Among them, the C3 protein of the complement system plays a major role in the immune system's recognition of foreign particles [2]. The concept of modifying the surface of vectors has therefore been applied in order to decrease the opsonisation process and the specific or non-specific recognition by MPS and blood components [3]. Heurtault et al.[4] developed lipid nanocapsules synthesised by a solvent-free method and covered by PEG 660 at high density, leading to really weak complement activation and low macrophage uptake [3,5]. In a previous work, the formulation of these nanocapsules was adapted to obtain DNA nanocapsules (DNA LNCs) [6]. Thanks to the use of oleic Plurol ® instead of Lipoid ® in their formulation, the lipid core allowed the entrapment of plasmid DNA molecules via the formation of lipoplexes (cationic liposomes of DOTAP:DOPE complexed with plasmid DNA). DNA LNCs were small (117 ± 10nm), suitable for an intravenous injection, but in vivo stability and blood half-life remained low and were ill-adapted to efficient in vivo transfection [6].To allow an extended circulation time, and consequently a higher tumor selectivity by passive accumulation through the EPR (enhanced permeability and retention) effect [7], we chose to modify the surface of our gene delivery systems, by inserting longer PEG chains at the sur...
Taken together, those data evidence that Tf-NPs represent an interesting nanomedicine to deliver anticancer drugs to glioma cells through systemic or locoregional strategies at early and late tumor stages.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.